If you take one thing from this article, let it be this: GLP-1 and hormones are not two separate stories. Midlife weight gain has hormonal drivers, early research suggests hormone therapy may influence how well GLP-1 medications work, and what happens to your muscle and bone during weight loss matters as much as the number on the scale. About 1 in 5 women aged 50 to 64 now report current or past GLP-1 use — the highest of any demographic in the US — so this conversation is not niche. It is the conversation. Here is what the evidence actually says, what it doesn't say yet, and what I pay attention to as a naturopathic doctor and clinical trial investigator.
Why does midlife weight gain feel so different?
Because it is different. As estrogen declines through perimenopause and menopause, fat storage shifts toward the abdomen, and insulin sensitivity worsens. That is why the habits that kept your weight stable at 32 can stop working at 46 without you changing a thing. This is not a discipline problem, and it is not in your head. It is physiology, and it is the backdrop against which every weight-loss tool — medication or not — has to work. When I sit down with a woman in her 40s who is frustrated with midlife weight gain, we start with her hormone health, because the hormonal terrain explains most of what she is experiencing.
What happens when GLP-1 and hormones are combined?
This is where the newest data comes in. At The Menopause Society's October 2026 annual meeting, researchers from Mayo Clinic Florida presented a real-world analysis of nearly 2,400 women on semaglutide and about 1,500 women on tirzepatide, all over 45 with a BMI over 27. The finding: women who were also on hormone therapy tended to lose more weight, and keep it off better, on some GLP-1 medications than women who were not on hormone therapy.
Now the part that matters as much as the finding. This was a retrospective, observational analysis — a look backward at real-world records — not a randomized trial. That means it can show an association, but it cannot prove hormone therapy caused the extra weight loss. Women on hormone therapy differ from women who aren't in many ways, and those differences can influence results. The Spanish Menopause Society has already cautioned that this data does not justify starting hormone therapy just to lose more weight on a GLP-1, and I agree with that caution. Hormone therapy is a decision with its own indications, benefits, and risks. What this study does is open an important door: the interaction between GLP-1 and hormones deserves proper randomized research, and women deserve clinicians who are watching it.
What is CagriSema, and should you be waiting for it?
You may see headlines about CagriSema, a next-generation combination of semaglutide plus cagrilintide. In a post-hoc analysis shared by the company, women averaged about 25% weight loss — and notably, the results held across premenopausal, perimenopausal, and postmenopausal stages. That menopause-stage breakdown is something I am glad to see, because women are usually an afterthought in obesity trials.
Hold the excitement at a reasonable level, though. Post-hoc means the analysis was done after the fact, in subgroups — a weaker form of evidence than a pre-planned primary result. CagriSema is investigational, not approved, with an FDA decision expected in late 2026. It may become an option; it is not one today, and no one should delay a health decision waiting for a drug that hasn't cleared review.
What is the risk nobody talks about: muscle and bone?
Here is my biggest clinical concern with rapid weight loss in midlife women, and it has nothing to do with willpower or side-effect headlines. When weight comes off quickly, some of what is lost is muscle and bone — tissue women in their 40s and 50s can least afford to lose, because we are already losing both to hormonal change. Muscle is metabolic currency: it protects your blood sugar, your strength, your balance, and your independence decades from now.
This is why I tell every woman on a GLP-1 that two things are non-negotiable companions to the medication: adequate protein at every meal, and resistance training, consistently. Not as a wellness garnish — as part of the treatment. GLP-1 muscle loss in women is preventable territory, but only if we treat it that way from day one instead of trying to rebuild later.
Why do hormones, gut health, sleep, and muscle decide how a GLP-1 works?
A GLP-1 changes appetite signaling. It does not fix your sleep, repair your gut, rebalance your hormones, or build your muscle. Those four things — hormones, gut health, sleep, and muscle — are the terrain that determines how well the medication works and, just as importantly, how you actually feel on it. This is the foundation of how I practice female longevity medicine: measure first, address root causes, and use every tool — including medication, when it's appropriate — in context rather than in isolation.
It is also why medication is never the only option on the table. If you are not ready for a GLP-1, or you want to build the foundation first, I have written about improving your weight without a GLP-1 — the same terrain work applies either way, and it makes any path work better.
Frequently asked questions
Do GLP-1 and hormones affect each other?
The honest answer is that the research is early but pointing somewhere interesting. A large real-world analysis presented in October 2026 found hormone therapy was associated with greater, more sustained weight loss on some GLP-1s, but it was observational — association, not proof. The hormonal changes of midlife themselves clearly affect weight, fat storage, and insulin sensitivity, whether or not medication is involved.
Should I start hormone therapy just to lose more weight on a GLP-1?
No. The Spanish Menopause Society has specifically cautioned against that reasoning, and I agree. Hormone therapy should be started for its own indications, after an individualized conversation about benefits and risks — not as a weight-loss booster based on retrospective data.
Can women in perimenopause use GLP-1 medications?
Many do, and the newest data is starting to include them — the CagriSema analysis reported results across pre-, peri-, and postmenopausal stages. What matters most in perimenopause is the surrounding plan: your hormones are shifting, so muscle protection, sleep, and lab monitoring deserve extra attention. This is a conversation to have with a clinician who knows your full picture.
How do I protect my muscle while losing weight on a GLP-1?
Treat protein and resistance training as part of the prescription, not optional extras. Eat adequate protein at every meal, lift or do resistance work consistently, and track your strength — not just your weight — over time. Rapid loss without that foundation costs you muscle and bone you need for the decades ahead.
What is CagriSema, and when will it be available?
CagriSema is an investigational combination of semaglutide and cagrilintide. A post-hoc company analysis showed about 25% average weight loss in women across menopause stages, but it is not FDA-approved, and a decision is expected in late 2026. Promising is not the same as proven or available.
Thinking about a GLP-1 — or already on one and wondering whether your hormones, labs, and muscle are being looked after? That is exactly what a first visit is for.
Book a free 10-minute discovery call, and let's talk through your picture — my practice is telehealth across California.
— Dr. Rubaina Dang
This article is general information only and is not medical advice. Talk with your own clinician about what is right for you.